A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
Checked against the public recordLast updated Jan 27, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- SynDevRx, Inc.
- Interventions being studied
- Drug: SDX-7320
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients have at least one site of radiographically measurable disease. * Eastern Cooperative Oncology Group (ECOG) status ≤1. * Adequate renal and liver functions. * Life expectancy ≥3 months. Exclusion Criteria: * Patients that have undergone organ transplant surgery. * The patient has a known history of Hepatitis A, B, or C and is on active anti-viral therapy. * History of gastric bypass surgery or banding procedure. * Uncontrolled or refractory hypertension: systolic \>180 or diastolic \>110, or hypotension: systolic \<90 or diastolic \<50 despite medical treatment. * Participation in any other trial of an investigational agent within 30 days prior to first dose of study drug. * The resting 12-lead electrocardiogram obtained during screening shows QTc (Fridericia correction) ≥470 ms or has a congenital prolonged QT syndrome.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- HonorHealth Research InstituteScottsdale, Arizona
- Cedars Sinai Medical CenterLos Angeles, California
- Sarah Cannon Research InstituteNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 27, 2020. Always confirm current availability with the study team.